Repligen Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Repligen stock.
View analyst ratings for Repligen or view top-rated stocks.

Wall Street analysts have given Repligen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Repligen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Repligen is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Repligen.

Repligen Co. (NASDAQ:RGEN) posted its earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.52 EPS for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.21. The biotechnology company earned $108.65 million during the quarter, compared to the consensus estimate of $93.89 million. Repligen had a net margin of 13.40% and a trailing twelve-month return on equity of 6.58%.
View Repligen's earnings history.

Repligen's stock was trading at $91.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGEN shares have increased by 127.0% and is now trading at $206.61.
View which stocks have been most impacted by COVID-19.

Repligen updated its FY21 earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of $1.86-$1.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.65. The company issued revenue guidance of $500-$525 million, compared to the consensus revenue estimate of $459.50 million.

5 Wall Street analysts have issued 12-month target prices for Repligen's shares. Their forecasts range from $150.00 to $251.00. On average, they expect Repligen's stock price to reach $219.00 in the next year. This suggests a possible upside of 6.0% from the stock's current price.
View analysts' price targets for Repligen or view top-rated stocks among Wall Street analysts.

13 employees have rated Repligen CEO Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among Repligen's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of RGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Square (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), The Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Christine Gebski, Glenn L Md Cooper, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends for Repligen.

RGEN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Pacer Advisors Inc..
View insider buying and selling activity for Repligen or or view top insider-buying stocks.

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGEN stock can currently be purchased for approximately $206.61.

Repligen has a market capitalization of $11.32 billion and generates $270.24 million in revenue each year. The biotechnology company earns $21.41 million in net income (profit) each year or $1.07 on an earnings per share basis.

Repligen employs 1,128 workers across the globe.

The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.

Repligen was founded in 1981.

The official website for Repligen is www.repligen.com.

Repligen is headquartered at 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at (781) 250-0111 or via email at [email protected]